Literature DB >> 23177263

Factors associated with the use of irreversible contraception and continuous use of reversible contraception in a cohort of HIV-positive women.

Nadia Kancheva Landolt1, Reshmie Ashmanie Ramautarsing, Nittaya Phanuphak, Nipat Teeratakulpisarn, Suteeraporn Pinyakorn, Piyanee Rodbamrung, Surasith Chaithongwongwatthana, Jintanat Ananworanich.   

Abstract

BACKGROUND: Effective contraception can be lifesaving by reducing maternal mortality linked to childbirth and unsafe abortion and by reducing vertical and horizontal transmission of HIV, in the case of an HIV-positive woman. STUDY
DESIGN: This study is a secondary analysis of a prospective cohort study. We assessed factors associated with the use of irreversible contraception and the continuous use of reversible contraception in HIV-positive Thai women. We used descriptive statistics to present baseline characteristics and logistic regression to assess the association between contraceptive use and factors in the study.
RESULTS: Of 196 women included in the analysis, 87% self-reported always using male condoms and 56% continuously using another effective contraceptive method during the period of the study (12-18 months). The choice of effective contraceptive methods was suboptimal--42% were sterilized, 14% used hormonal contraception and no participant reported the use of an intrauterine device. Sexual activity and past contraceptive use were factors associated positively with current continuous contraceptive use. Live births and lower levels of education were additional factors associated positively with sterilization.
CONCLUSIONS: Despite high contraceptive use, there are still uncovered contraceptive needs among HIV-positive women in Thailand. HIV-positive women need established specialized family planning services, offering an optimal variety of contraceptive choices and tailored to their individual needs. As sterilization is an irreversible choice, it cannot be a viable alternative for every woman. Due to the positive trend between current and past contraceptive use, we consider that it may be possible to improve family planning programs if they start as early as possible in a woman's life and are continued throughout her sexually active and reproductive years.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23177263     DOI: 10.1016/j.contraception.2012.10.017

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  A systematic review of contraceptive continuation among women living with HIV.

Authors:  Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones
Journal:  Contraception       Date:  2018-02-09       Impact factor: 3.375

Review 2.  The role of family planning in elimination of new pediatric HIV infection.

Authors:  Rose Wilcher; Tricia Petruney; Willard Cates
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

3.  Fertility desires and unmet need for family planning among HIV infected individuals in two HIV clinics with differing models of family planning service delivery.

Authors:  Rhoda K Wanyenze; Joseph K B Matovu; Moses R Kamya; Nazarius M Tumwesigye; Maria Nannyonga; Glenn J Wagner
Journal:  BMC Womens Health       Date:  2015-01-28       Impact factor: 2.809

4.  Strategies to improve the uptake of effective contraception in perinatally HIV-infected adolescents.

Authors:  Nadia Kancheva Landolt; Jullapong Achalapong; Pope Kosalaraksa; Witaya Petdachai; Chaiwat Ngampiyaskul; Stephen Kerr; Pongrak Boonyanurak; Jintanat Ananworanich; Torsak Bunupuradah
Journal:  J Virus Erad       Date:  2017-07-01

5.  Dual contraceptive method use and pregnancy intention among people living with HIV receiving HIV care at six hospitals in Thailand.

Authors:  Warangkana Munsakul; Rangsima Lolekha; Boonchai Kowadisaiburana; Anuvat Roongpisuthipong; Supannee Jirajariyavej; Suvanna Asavapiriyanont; Ubonsri Hancharoenkit; Benjamas Baipluthong; Sarika Pattanasin; Michael Martin
Journal:  Reprod Health       Date:  2016-02-03       Impact factor: 3.223

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.